Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharma Inc (NQ: ANIP )

61.68 +1.16 (+1.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,521
Open 61.01
Bid (Size) 58.14 (1)
Ask (Size) 68.80 (1)
Prev. Close 60.52
Today's Range 60.34 - 61.99
52wk Range 48.20 - 70.81
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
+7.85%
+7.85%
1 Month
-0.56%
-0.56%
3 Month
-2.45%
-2.45%
6 Month
+2.37%
+2.37%
1 Year
-3.34%
-3.34%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Via Benzinga
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Via InvestorPlace
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
Via Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Earnings Scheduled For February 29, 2024
Via Benzinga
ANI Pharmaceuticals's Earnings Outlook
Via Benzinga
Expert Ratings for ANI Pharmaceuticals
Via Benzinga
Analyst Expectations for ANI Pharmaceuticals's Future
Via Benzinga
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
Via Investor's Business Daily
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
Via Benzinga
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into ANI Pharmaceuticals's Return On Capital Employed
Via Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
Via InvestorPlace
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ANI Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.